6533b854fe1ef96bd12af62c

RESEARCH PRODUCT

Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain : a descriptive analysis

Javier QuinteroJosep Antoni Ramos-quirogaJavier San SebastiánFrancisco MontañésAlberto Fernández-jaénJose Martinez-ragaMarta García GiralMontserrat GraellMaría J. MardomingoCésar SoutulloJesús EirisMontserrat TéllezMontserrat PamiasJavier CorreasJuncal SabatéLaura García-ortiJosé A. AldaUniversitat Autònoma De Barcelona. Departament De Psiquiatria I De Medicina Legal

subject

EmploymentMaleAdolescentlcsh:RC435-571Cross-sectional studyTotal costTrastorns de l'atenció03 medical and health sciencesIndirect costs0302 clinical medicineCost of Illnesslcsh:PsychiatrySchool childrenHealth caremedicineHumansAttention deficit hyperactivity disorderADHD0501 psychology and cognitive sciencesPsiquiatriaChildAverage costhealth care economics and organizations*Economic evaluationDemography*School childrenDescriptive statisticsbusiness.industry*Adolescence05 social sciencesHealth Care Costsmedicine.diseaseEconomic evaluationAdolescencePsychiatry and Mental healthCross-Sectional StudiesCaregiversAttention Deficit Disorder with HyperactivitySpainEconomic evaluationFemale*ADHDbusiness030217 neurology & neurosurgeryResearch Article050104 developmental & child psychologyDemography

description

Background Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition in childhood (5.3% to 7.1% worldwide prevalence), with substantial overall financial burden to children/adolescents, their families, and society. The aims of this study were to describe the clinical characteristics of children and adolescents with ADHD in Spain, estimate the associated direct/indirect costs of the disorder, and assess whether the characteristics and financial costs differed between children/adolescents adequately responding to currently available pharmacotherapies compared with children/adolescents for whom pharmacotherapies failed. Methods This was a multicenter, cross-sectional, descriptive analysis conducted in 15 health units representative of the overall Spanish population. Data on demographic characteristics, socio-occupational status, social relationships, clinical variables of the disease, and pharmacological and non-pharmacological treatments received were collected in 321 children and adolescents with ADHD. Direct and indirect costs were estimated over one year from both a health care system and a societal perspective. Results The estimated average cost of ADHD per year per child/adolescent was €5733 in 2012 prices; direct costs accounted for 60.2% of the total costs (€3450). Support from a psychologist/educational psychologist represented 45.2% of direct costs and 27.2% of total costs. Pharmacotherapy accounted for 25.8% of direct costs and 15.5% of total costs. Among indirect costs (€2283), 65.2% was due to caregiver expenses. The total annual costs were significantly higher for children/adolescents who responded poorly to pharmacological treatment (€7654 versus €5517; P = 0.024), the difference being mainly due to significantly higher direct costs, particularly with larger expenses for non-pharmacological treatment (P = 0.012). Conclusions ADHD has a significant personal, familial, and financial impact on the Spanish health system and society. Successful pharmacological intervention was associated with lower overall expenses in the management of the disorder. Electronic supplementary material The online version of this article (10.1186/s12888-017-1581-y) contains supplementary material, which is available to authorized users.

10.1186/s12888-017-1581-yhttps://ddd.uab.cat/record/187885